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Abstract
CLN5 disease is a rare form of late-infantile neuronal ceroid lipofuscinosis (NCL) caused by mutations in the CLN5 gene
that encodes a protein whose primary function and physiological roles remains unresolved. Emerging lines of
evidence point to mitochondrial dysfunction in the onset and progression of several forms of NCL, offering new
insights into putative biomarkers and shared biological processes. In this work, we employed cellular and murine
models of the disease, in an effort to clarify disease pathways associated with CLN5 depletion. A mitochondria-focused
quantitative proteomics approach followed by functional validations using cell biology and immunofluorescence
assays revealed an impairment of mitochondrial functions in different CLN5 KO cell models and in Cln5−/− cerebral
cortex, which well correlated with disease progression. A visible impairment of autophagy machinery coupled with
alterations of key parameters of mitophagy activation process functionally linked CLN5 protein to the process of
neuronal injury. The functional link between impaired cellular respiration and activation of mitophagy pathways in the
human CLN5 disease condition was corroborated by translating organelle-specific proteome findings to CLN5
patients’ fibroblasts. Our study highlights the involvement of CLN5 in activation of mitophagy and mitochondrial
homeostasis offering new insights into alternative strategies towards the CLN5 disease treatment.
Introduction
The Neuronal ceroid lipofuscinoses (NCL) are the most
common inherited progressive encephalopathies of
childhood characterized by epilepsy, blindness, dementia,
motor impairment and premature death. Based on clin-
ical, pathological, and molecular criteria, fourteen differ-
ent forms of NCL have been described so far, associated
with nearly 400 mutations (mostly autosomal recessively
inherited) in 13 genes (CLN1-8, CLN10-14). The diag-
nosis of NCL is based on mutation analysis, but precise
definition is substantiated by morphological findings,
through the characteristic storage deposits which are
specific for each form1,2. NCL specific ultrastructural
patterns encompass GRODs (osmiophilic granular
deposits seen in CLN1, CLN4, CLN10) and non-GROD
features (curvilinear, rectilinear profiles or fingerprint
profiles appearing either separate or in combination in
other forms), the latter correlating with accumulation of
the subunit c of ATP synthase (SCMAS)1–3. Currently, no
treatment is available for any form of NCL, although a
cohort of CLN2 patients undergoes an enzymatic repla-
cement therapy4,5.
The “non-enzymatic” CLN5 disease (MIM 256731)
represents a rare, late infantile form caused by mutation
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in the CLN5 gene encoding a soluble, yet uncharacterized,
lysosomal matrix glycoprotein which appears to be
involved in endocellular trafficking at endoplasmic reti-
culum, Golgi and endosomes levels as well as in con-
trolling the itinerary of lysosomal sorting receptors. In
childhood, the disease exhibits a relatively slowly pro-
gressive course advancing further with visual failure,
motor and mental decline, ataxia, myoclonus and epi-
lepsy. Few postmortem pathologies are seen in CLN5
patients, as usually brains display early and pronounced
atrophy in the cerebellum accompanied by storage
deposition, destruction of cerebral neurons, astrocytosis
and myelin loss6. Death usually occurs early in life,
between the second and the fourth decade. A recent
natural history study of the CLN5 disease highlighted the
presence of two groups of patients with different clinical
severity defining the conditions for experimental or
disease-modifying treatments within the first 3 years of
the disease7, as thereafter, high variability in rate of
decline is evident in patients based on mutation type and
residual levels of CLN5 protein.
Various CLN5 disease models have been described so
far including ovine, bovine, and canine (https://www.ucl.
ac.uk/ncl/animal.shtml). Cln5 knockout (Cln5−/−) mice
demonstrate a prominent homology to human pathol-
ogy8,9, suffering from several neurological defects with
relatively late onset including brain atrophy, visual/cog-
nitive and mild motor dysfunction, and a marked glial
activation and hypomyelination preceding neuronal loss,
mostly pronounced in the thalamocortical system. In
marked contrast to other forms of NCL, neuronal loss in
this model starts in the cortex and only subsequently
occurs within thalamic relay nuclei10. Defective myelina-
tion has instead been observed in vitro and in the devel-
oping brain, accompanied by the malfunctioning of
sphingolipid transport11.
Mitochondrial dysfunction is commonly involved in the
pathogenesis of neurodegenerative disorders since neu-
rons highly depend on oxidative phosphorylation for their
energy supply and have low capacity to upregulate gly-
colytic ATP generation. Defects in the mitochondrial
compartment have been hypothesized in various NCL
subtypes12–16, and appear to play relevant roles in the
initiation of the apoptotic cascade, known as the basis of
neuronal injury. The hypothesis of a mitochondrial dys-
function in NCL is supported by in vitro studies showing
alterations of the mitochondrial network in CLN1 and
CLN6 patients’ cells, low levels of expression of mito-
chondrial proteins and the implication of pathways lead-
ing to apoptosis in CLN1 disease13. The crosstalk of
several mitochondrial carriers implicated in protein fold-
ing/sorting with CLN1, CLN3, and CLN5 proteins14,
revealed in the interactomics studies, is marked. Changes
in the level of expression of mitochondrial proteins were
also observed in both thalamus and cerebral cortex of
symptomatic Ppt1−/− mice, with decreased levels of
cytochrome c oxidase subunit 7C and two subunits part of
the F0-ATP synthase. Furthermore, a quantitative analysis
of PPT1 interaction partners in human neuroblastoma
cells identified seven mitochondrial proteins including
components of the pyruvate dehydrogenase and ATP
synthase complexes and voltage dependent anion channel
protein 212,17,18. Although the precise function of many
NCL causative proteins remains to be fully elucidated, the
aforementioned findings point to a significant contribu-
tion of mitochondrial dysfunction in the onset and pro-
gression of the disease.
In this work, by employing quantitative mitochondrial
proteomics and functional studies, we identified new
disease-relevant functions of CLN5 protein and factors
modifying the disease status. Mitochondrial fractions
were derived from CLN5 knockout cells and cerebral
cortex in pre-symptomatic and symptomatic Cln5−/−
mice. Initially, for proof-of principle experiments, HEK
293T cells were selected given their easy handling, well
suited for CRISPR/Cas9 gene editing. More robust func-
tional analyses were subsequently performed in SH-SY5Y
human neuronal-like cells, a model commonly used in
studies related to neurodegenerative diseases, oxidative
stress19,20, and other NCL forms12,17,21. Mitochondria-
focused quantitative proteomics in CLN5 knockout cells
highlighted the mitophagy process and changes in mito-
chondrial function accompanied by elevation of an oxi-
dative stress, and these altered processes were observed in
the Cln5−/−mouse model, already at the early stage of the
disease. Finally, CLN5 patients’ skin fibroblasts were used
to bridge the experimental paradigm to human pathology
and to pinpoint dysregulated mitochondrial pathways.
Results
Molecular features of CLN5 KO cells and patients’
fibroblasts involved in this study are presented in the
supplementary material.
Analysis and bioinformatic categorization of differential
mitochondrial proteome profiles
The proteomic profiling of mitochondrial fractions from
two HEK 293T KO clones (#8, #9b) was performed and
the results compared to the control cells22. Organelle-
specific proteome profiling revealed 62 mitochondrial
differentially expressed proteins (mtDEPs); among these
46 mtDEPs were down-regulated and 16 up-regulated
(Fig. 1a). Supplementary Table S2 lists the full dataset.
Categorization of mtDEPs was performed through the use
of Ingenuity Pathway Analysis (IPA)23. Specifically, we
identified canonical pathways related to mitochondrial
dysfunction and oxidative phosphorylation, whereas
among the affected disease and functions, mitochondrial
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membrane potential, ATP synthase, mitochondrial dis-
order, modification of ROS, morphology of mitochondria,
consumption of oxygen and metabolism of hydrogen
peroxide were pinpointed among others. A molecular
network encompassing 22 identified mtDEP is reported in
the Supplementary Fig. S2a. Similar functional associa-
tions were also seen in the analysis based on the Gene
Ontology (GO), highlighting processes related to
bioenergetic metabolism, oxidative stress and protein
folding (Supplementary Fig. S2b).
The mitochondrial proteome analysis was also carried
out in preparations obtained from homozygous Cln5−/−
and wild-type littermates, age matched control male mice.
Pre-symptomatic (3 months) and symptomatic (9 months)
stages were investigated. Data filtering allowed the
identification of 12 DEPs with high and medium
Fig. 1 Bioinformatic examination of differential proteome profiles in analyzed disease models. a Left panel, nested pie chart describing the
filtering strategy adopted for quantitative proteomics data in the CLN5 knockout cell model. The number of quantified mitochondrial proteins is
shown, selected based on their high and medium mitochondrial confidence (filter 1). Only these mitochondrial proteins, which passed the criterion
of differential fold change ratio, FC > 1.5, based on quantitation utilizing ≥2 unique peptides and p value ≤ 0.05 by Anova, (mtDEPs; Filter 2) served as
targets in bioinformatic surveys. Right panel, volcano plot depicting the proteomic profiles of selected mtDEPs in the cell model showing down-
regulation of several mitochondrial proteins. b A similar filtering strategy was also applied to a Cln5 −/− mouse model (FC > 1.3, ≥2 unique peptides
and p value ≤ 0.05 by Anova). Heat map of IPA canonical pathway analysis reporting the most significantly affected pathways according to the
disease progression. c Bar chart representation of affected canonical pathways identified in different disease models with the lowest predicted p
values. The number of mitochondrial DEPs assigned to each category is presented.
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mitochondrial confidence in presymptomatic Cln5−/−
mice (11 down-regulated and one up-regulated), while
profiling experiments at the symptomatic stage revealed
11 mtDEPs, including four down-regulated and seven up-
regulated ones (Fig. 1b). Comparative analysis focusing on
changes in biological states across the disease progression
indicated a significant impairment of oxidative phos-
phorylation term already at the presymptomatic stage
with statistical significance increasing during the disease
course (Fig. 1b). Common altered processes related to
mitochondrial metabolism included NAD phosphoryla-
tion/dephosphorylation, TCA cycle and superoxide radi-
cals degradation occurred to be significantly affected early
in the pathogenesis of CLN5 disease. Common pathway
elements were also identified by comparing the analyzed
disease models. Both cells and mice CLN5 models indi-
cated associations linked to dysregulation of mitochon-
drial function (Fig. 1c). In summary, bioinformatic surveys
highlighted the functional association related to loss of
CLN5 protein expression and impairment of mitochon-
drial compartment, thereby linking CLN5 to mitochon-
drial dysfunction.
Protein expression of selected mtDEPs
To cross validate the proteomics data with direct mea-
surement of protein expression levels using WB, among
mtDEPs detected in HEK 293T KO model, we selected
proteins relevant to cellular respiration (ACO2 and
ATP5L) and mitophagy process (FUNDC; Fig. 2a).
Immunoblotting with specific antibodies corroborated the
results of proteomic profiling demonstrating a significant
downregulation of analyzed proteins in HEK 293T KO
cellular lysates. Similarly, reduced levels of ACO2 and
ATP5L were traced in SH-SY5Y KO cells whereas
FUNDC expression was undetectable in neuroblastoma
lysates.
Analysis of cellular respiration in CLN5 models
Bioinformatic scrutiny of differential proteome profiles
highlighted pathways related to mitochondrial dysfunc-
tion. In order to investigate the functional consequence of
alterations in annotated proteins, we assessed micro-
oxygraphy in SH-SY5Y model. Compared to the control
cells, we observed a decreased basal and maximal oxygen
consumption rate (OCR) without significant difference in
non-mitochondrial respiration in SH-SY5Y KO cells (Fig.
2b). Even though basal rate of respiration could not
adequately reflect the ability of cells to cope with an
increased energy demand, the maximal respiration is a
good estimate of the maximum capacity for mitochondrial
substrate oxidation24. Furthermore, normal non-
mitochondrial respiration parameter indicated that loss
of CLN5 expression leads to impairment of cellular
respiration in KO cells. Spectrophotometric determination
of RC enzymes activity in cerebral cortex from sympto-
matic Cln5−/− mice revealed multiple defects with sig-
nificant reduction of complexes III and I+ III and an
increase of citrate synthase (CS) activity, a validated index
of mitochondrial mass (Fig. 2c). In contrast, no significant
differences were measured in heart tissue from affected
mice, an organ that is not involved in the pathogenesis of
CLN5 disease (data not shown).
Analysis of mitophagy in CLN5 models
Qualitative analysis of mitochondrial network and measure-
ments of mitochondrial membrane potential
To investigate how impaired cellular respiration related
to CLN5 deficiency impacts on mitochondrial structure,
we imaged the shape of the mitochondrial reticulum in
SH-SY5Y KO cells. When compared to the empty vector
control line, the staining of neuroblastoma KO with
MitoTracker Red CMXRos dye and anti-VDAC1 mono-
clonal antibody (two mitochondrial markers) revealed a
fragmented mitochondrial network with an altered dis-
tribution around the nuclei (Fig. 3a), as previously
observed in primary cells from cases with CLN1 disease13.
Moreover, chloromethyl-X-rosamine (CMXRos) accu-
mulation, which is dependent on membrane potential,
was reduced in SH-SY5Y KO cells suggesting a decrease
in the mitochondrial membrane potential (ΔΨm).
Reduction of ΔΨm was further assessed by staining the
neuroblastoma cells with TMRM probe revealing a
reduced mitochondrial membrane potential in KO cells in
terms of both probe accumulation and membrane
potential maintenance. Furthermore, in KO cells treat-
ment with oligomycin, which blocks proton transit
through CV, highlighted an increased leakage of the inner
mitochondrial membrane independently of ATP synthesis
(Fig. 3b). In conclusion, ΔΨm is a key component in the
mitophagy pathway and the reduction of this parameter
or its dissipation over time involves mainly non-fusing
mitochondria, and is closely related to the depolarization
events induced by ROS overproduction25,26.
Evaluation of the redox state in CLN5 KO SH-SY5Y cells
Due to their role in metabolism, mitochondria are very
susceptible to oxidative stress and formation of ROS as a
mitochondrial waste product eventually leads to cyto-
toxicity and cell death. To verify the redox state of cells
lacking CLN5, hydroxyl, peroxyl and other reactive oxy-
gen species were investigated using the cell permeant
fluorogenic dye H2DCFDA. Both in regular medium (RM)
and under stress conditions (short-term treatment with
TBHP as a source of free radicals), we observed a sig-
nificantly increased formation of ROS in KO versus
controls SH-SY5Y cells, indicating an increased suscept-
ibility to oxidative stress (Fig. 3c).
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Monitoring mitophagy through the expression of mitochon-
drial probes and markers of the autophagy machinery
In mitophagy, mitochondrial fragmentation is closely
linked to autophagosome formation. In KO cells, using
TOMM20 and LC3 as markers of mitochondria and
autophagosomes, respectively, we observed distinct co-
localization of both markers, particularly evident under
FCCP treatment, suggestive for an activated mitophagy
process (Fig. 4a). Both ATP depletion and oxidative stress
contribute to activation of the stress-induced mitophagy
pathways, and damaged mitochondria tend to fragment27.
This alteration in mitochondrial dynamics occurs simul-
taneously with autophagosome formation, a pathway
known to be implicated in NCL, including CLN528,29. In
SH-SY5Y KO cells we further demonstrated an autop-
hagosome accumulation by double staining with LAMP1
(lysosomal marker) and LC3 (autophagosome marker; Fig.
4b), and a significant increase in LC3-II/LC3-I ratio, both
in basal condition and after mitophagy activation with
20 µM FCCP for 2 h (Fig. 4c).
Relevance to human CLN5 disease
To rapidly assess whether the mitochondrial changes
seen upon proteome profiling and functional studies in
KO cells and mice were relevant to the CLN5 disease, we
selected three fibroblast primary lines with biallelic
Fig. 2 Functional and expression validation of proteomic data. a Validation of protein expression levels related to selected mtDEPs, assessed in
HEK 293T and SH-SY5Y whole cell lysates. Densitometric analyses corroborate the results of mitochondrial proteome profiling. b Analysis of
mitochondrial energy metabolism in neuroblastoma cells CLN5 KO using the Seahorse XF Cell Mito Stress Test, shows a decreased basal oxygen
consumption rate as well as maximal respiration whereas no significant differences were observed in non-mitochondrial respiration. c
Spectrophotometric determination of RC enzymes in cerebral cortex from symptomatic mice reveals a general OXPHOS impairment with a
significant reduction of complexes III and I+ III and increase of citrate synthase activity as index of mitochondrial proliferation. Data represent the
mean (± standard deviation) of three independent experiments (n= 9). Statistical significance was determined by two-tailed Student t test *p < 0.05;
**p < 0.01; ***p < 0.001.
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mutations in the CLN5 gene and the reduced expression
of CLN5 protein7. Two patients (2/F and 11/M) with a
severe reduction of CLN5 protein (Fig. 5a) showed a
dramatic reduction of basal and maximal OCR (Fig. 5b)
and an increased expression of p62 (Fig. 5c), suggestive for
a block of autophagosome-lysosome maturation30. Cor-
respondingly, ultrastructural investigations of patients’
fibroblasts in vitro showed increased amounts of both
lysosomes and vacuoles containing densely packed,
osmiophilic material (Fig. 5d). Taken together, the mito-
chondrial changes observed in disease models were suc-
cessfully replicated in CLN5 patients’ cells.
Discussion
This study illustrates a functional proteomics strategy
defining a new mitochondrial role of CLN5 protein in
disease models and primary cells from NCL patients. We
used KO neuronal-like cells and brain tissues from a
published Cln5−/− mice strain9 and utilized label-free
quantitative proteomics targeting mitochondria, thereby
reducing the complexity of samples. Identification of
DEPs specifically linked to mitochondrion resulted in
focused functional assessments, specifically pinpointing
lowered levels of oxygen consumption and ATP produc-
tion in KO cells, multiple defects in RC enzyme activities
Fig. 3 Analysis of the mitophagy-related parameters in CLN5 cell model. a Mitochondrial network organization in SH-SY5Y KO model. When
compared to the empty vector control line, CLN5 KO cells reveal an altered mitochondrial network with increased fragmentation both after
Mitotracker red and VDAC staining. MT red CMXRos probe accumulation, which is dependent upon membrane potential, is reduced in KO lines
suggesting a decreased ΔΨm. Figure shows representative images from three independent cell staining. Scale bar, 10 µm. Inserts show a 3x
magnification. b Neuroblastoma cells were stained with TMRM probe revealing in CLN5 KO line a reduced mitochondrial membrane potential both in
terms of probe accumulation and membrane potential maintenance. End-point assay indicates a mitochondrial membrane depolarization in KO cells
reported as average TMRM relative fluorescence units RFU ± SD subtracting the fluorescence related to FCCP treatment. Data were normalized by
DAPI staining as a function of cell number. Kinetic track demonstrates a differential ability between KO and control cells to maintain polarized the
mitochondrial membrane particularly after oligomycin blocking proton transit through Complex V, highlighting any leakage of inner mitochondrial
membrane. FCCP was added at the end of the experiments to fully depolarized mitochondrial to demonstrate specificity of the acquired
measurements. c Redox state of cells lacking CLN5 using the fluorogenic dye H2DCFDA shows a significantly larger amount of ROS in SH-SY5Y CLN5
KO cells as compared to controls both in regular medium (RM) and under stress condition (short-term TBHP treatment). Data represent the mean (±
standard deviation) of three independent experiments (n= 9). Asterisks indicate statistical significance of Ctrl versus KO cells in the presence/absence
of TBHP treatment, as determined by the Student t test. ***p < 0.001.
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in Cln5−/− mice, abnormal organization of the mito-
chondrial network and increased ROS production31,32.
These results implicate CLN5 in mitochondrial func-
tion. Along with other NCL proteins, CLN5 is a known
partner of the F1 subunit c of ATP synthase, essential for
mitochondrial ATP synthesis33 and interacts with mito-
chondrial carriers involved in the protein folding/sorting
proteins, some of those are shared with other NCL pro-
teins (i.e. CLN1 and CLN314). Our findings propose CLN5
as a new player in the complex dynamics of mitochondria
and potentially relevant to mitochondrial fusion/fission.
Mitochondrial shape is closely linked to the function since
morphological adaptations are crucial for many physio-
logical processes such as cell cycle, immunity, apoptosis
and mitochondrial quality control34. A damaged network
has been reported in animal models for NCL15,16, and
more recently, different patterns and degree of dis-
organization of mitochondrial cristae have been reported
in iPSCs obtained from reprogramming CLN3 patients’
fibroblasts, cerebellar precursor cells in a Cln3Δed7/8 and
primary cultures from Cln3−/− neurons35–37. Further-
more, oxidative phosphorylation is critical especially for
neurons, in which the compensatory capacity of the gly-
colytic pathway to generate ATP is particularly ineffective.
In this scenario, CLN5 seems to drive the appropriate
mitochondrial shape, function, and distribution within the
cell, a role not previously envisaged. This would prompt
enhanced oxidative stress and bioenergetic failure, the
abnormalities already seen in lysosomal storage disorders
including several forms of NCL38–40.
The combination of protein molecular signatures and
immunofluorescence validation in neuronal-like KO cells
suggests mitophagy as a novel aspect in the pathogenesis
of CLN5 disease. The reduction of ΔΨm triggers the
mitophagy pathway that induces autophagosome forma-
tion around defective mitochondria. This feature is
Fig. 4 Dysregulation of autophagy and mitophagy machinery in CLN5 disease. a Colocalization of mitochondria (marked by TOMM20) and
autophagosomes (marked by LC3) was markedly increased in SH-SY5Y CLN5 KO cells (arrows, yellow fluorescence), and strongly associated with FCCP
treatment to stimulate mitophagy (right panel, 20 µM FCCP). Scale bar, 10 µm. b An increase in co-localization of LC3 (in green) and LAMP1 (in red)
marked by yellow fluorescence suggested a compromising cargo degradation in SH-SY5Y CLN5 KO cells with dysregulated autophagosome-
lysosome fusion. DAPI (blue fluorescence) was used to stain nuclei. Scale bar, 10 µm. a, b show representative images from three independent cell
staining. c Western blotting analysis of the autophagy marker LC3 in SH-SY5Y cells indicates a significant reduction in the level of the autophagic flux
(LC3BII/LC3BI ratio), exacerbated by the addition of 20 µM FCCP. Data represent the mean (± standard deviation) of three independent experiments
(n= 9). Student t test. ns not statistically significant; *p < 0.05; **p < 0.01; ***p < 0.001.
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supported by the observed dysregulation in expression of
FUN14 domain-containing protein (FUNDC) (Fig. 2a, b),
which is believed to serve as mitophagy receptor in
mammals, and SQSTM1/p62 (Fig. 5d), thereby linking
mitochondria with the autophagy mechanism in different
cell types41. Moreover, SH-SY5Y KO cells demonstrated
Fig. 5 Translational confirmations in patient’ skin fibroblasts. a CLN5 protein levels, measured by Western Blotting, show a full lacked CLN5-
immunoreactivity in Pt 2/F and 11/M, whereas a different CLN5 expression pattern is shown in patient 6/M, likely due to different effects of CLN5
mutations exerted on protein synthesis. Immunochemical studies demonstrate that subunit c of mitochondrial ATP synthase (SCMAS), the
characteristic hallmark in NCL5, is stored in intracellular aggregates in patients’ fibroblasts. Scale bar, 10 µm. b Micro-oxygraphy track shows a reduced
OCR, which is clearly evident after FCCP injection, reflecting a deficient spare respiratory capacity. Moreover, under oxidative conditions (blocking
glycolysis with 2-deoxy-D-glucose + pyruvate) a reduced ATP content and bioenergetics defects in patients with more severe mutations and less
abundant protein levels are seen. G glucose used as source for ATP production; O oligomycin, used to block mitochondrial respiration; 2DG+ P= 2-
deoxy-D-glucose plus pyruvate, used to block glycolysis. c Fibroblast pellets were fixed with 1.25% glutaraldehyde and 0.5% paraformaldehyde in
phosphate buffer, post-fixed in 1% osmium tetraoxide and stained with uranyl acetate and lead citrate. Abnormal cytoplasmic pattern is marked, as
demonstrated by the increased amount of vacuoles, dense bodies and lysosomes (A and B). Osmiophilic figures with different ultrastructural
arrangement, including honeycomb structures can be observed (insert A), but classical cytosomes are not detectable. Several vacuoles, outlined by a
single membrane and containing osmiophilic material, are consistent with features of autophagic process. Osmiophilic inclusions featuring
multilamellar structures can be detected within the vacuoles (insert B). Scale bar= 1.0 µm; insert A, scale bar= 0.2 µm; insert B, scale bar= 0.3 µm.
d Western Blotting analysis reveals significantly increased expression of p62 in patients’ fibroblasts, consistent with a block of autophagosome-
lysosome maturation. Data represent the mean (± standard deviation) of three independent experiments (n= 9). Statistical significance was
determined by the Student t test. *p < 0.05; **p < 0.01; ***p < 0.001.
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compromising cargo degradation combined with
increased co-localization of mitochondria and autopha-
gosome markers TOMM20 and LC3 (Fig. 4a), suggestive
for mitophagy activated process. By scrutinizing GO
biology and pathway data with results of functional
mitochondrial assessments in this work, it seems plausible
to speculate that impaired mitophagy represents a possi-
ble inducer of the process of neuronal injury, associated
with reduced synapse formation and impaired neur-
itogenesis. It is noteworthy that severe axonal degenera-
tion and increased neurogenesis have been demonstrated
in Cln5-deficient mice42. Mitochondrial dysfunction and
defective mitophagy have also been associated with more
common neurodegenerative diseases including Parkin-
son’s disease and Frontotemporal dementia43–45, and the
precise characterization on these associated phenomena
could likely offer new opportunities for molecular targets
in NCL therapy.
In this work, we demonstrate that the aforementioned
mitochondrial roles and mitophagy are relevant to CLN5
disease and the cortical brain involvement seen in NCL.
Contrary to heart tissue, murine cerebral cortices showed
a trend towards downregulation in expression of mito-
chondrial proteins and related-dysregulated processes
(Fig. 1b), already at the pre-symptomatic stage (age
3 months).
An implication of mitochondrial dysfunction and TCA
cycle II has previously been reported in a proteomic study
of pre-symptomatic thalami in Ppt1−/− mice12. Moreover,
comparing our dataset with ones generated by previous
proteomic studies12,14,46, a considerable overlap between
mtDEPs identified in Ppt1−/−, Tpp1−/− mouse studies,
and CLN3/CLN5 interaction partners has been identified
(Supplementary Table S4). Shared mitochondrial carriers
(MDH2, PITRM1, SLC25A3, SPNS1), proteins implicated
in apoptotic (CARL, CLIC4, YWHAQ) and metabolic
processes (AK2, DLST, ECI1, HKDC1, GANAB), astro-
cyte development (VIM), mitochondrial organization
(CHCHD3, VAT1) and energy production (NDUFV2,
ENO1) further reinforces the hypothesis of a common
molecular theme14,47,48 and neuronal impairment in
NCLs (Fig. 6). Furthermore, we noticed multiple defects
in RC enzyme complexes (I+ III and III) in cerebral
cortex (Fig. 2c). Decreased activities of respiratory chain
complexes have already been recognized in various forms
of NCL15,16,49 including CLN113, but it is unclear if this is
a consequence of compromised fission/fusion metabolism
or it is linked to other proteolytic impairments50.
Importantly, primary cells from CLN5 patients recapitu-
lated the findings observed in CLN5 models (i.e., reduced
oxidative metabolism and elevated ROS production) in
relation to the disease status and protein residual activity
indicating that dysfunction in mitochondrial energy
homeostasis is relevant to human disease and its
progression.
The proteomic approach utilizing compartment tar-
geted, label-free quantitative mass spectrometry is well
suited to reveal specific changes and characterize disease-
associated functional modules. The possibility to analyze
affected animals at different disease progression stage,
allowed us to identify and compare common molecular
processes related to progression or shared with other
NCL forms. In our example, functional proteomics
revealed mitochondrial involvement in disease patho-
genesis, which might serve to define new putative targets
of therapeutic interest in CLN5 disease. The specific
information about the role of autophagy and impaired
mitochondrial function could have an impact on patho-
genetic processes involved in neuronal injury and on the
broad meaning of “lysosomal” pathogenesis hypothesized
in more frequent neurodegenerative diseases leading to
dementia in children and adults3,51.
Material and methods
Cell cultures
HEK 293T cell line (293T ATCC® CRL-3216™), derived
CRISPR KO (hereafter called KO) and empty-vector
px459 expressing cells (hereafter named as Ctrl) were
cultured in DMEM containing 10% FBS, 4.5 g/L glucose
and 1% penicillin/streptomycin, supplemented with
L-glutamine to achieve a final concentration of 6 mM.
Neuroblastoma cell line (SH-SY5Y ATCC® CRL-2266)
and derived KO and Ctrl clones were cultured in MEM/
F12 1:1 with 10% FBS, 2 mM L-glutamine, 1% penicillin/
streptomycin. Human fibroblasts were collected
Fig. 6 Schematic diagram of the identified processes underlying
CLN5 disease models and patient material. Functional studies
corroborate the bioinformatic analyses of differentially expressed
mitochondrial proteins linking the lack of CLN5 with oxidative stress,
bioenergetic impairment, and autophagy induction resulting in an
activation of mitophagy process.
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according to standard procedures from diagnostic skin
biopsies. Patients’ parents signed an informed consent
form for skin biopsy, authorizing research purposes in
accordance with our Tuscany Region Ethic committee.
Primary fibroblast cell lines from CLN5 patients carrying
different mutations in CLN5 have been described before7,
and were grown at 37 °C with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM), containing 10% fetal
bovine serum (FBS), 4.5 g/L glucose and 1% antibiotics/
antimycotics. All cell lines have been tested for myco-
plasma contamination.
Cln5−/− mouse model and tissue collection
The CLN5 mouse model of late infantile Finnish variant
of NCL was originally generated at the University of
Helsinki9, by disrupting exon 3 of a mouse Cln5 gene,
with a resulting premature stop codon in exon 4 of the
murine gene. Animals involved in this study were made
available by the A.I. Virtanen Institute for Molecular
Sciences, University of Eastern Finland, Kuopio. Both
male and female mice at pre-symptomatic (3 months) and
symptomatic stages (9 months) were used. Age matched
wild-type siblings served as controls. A complete list of
mice employed in this study is reported in Supplementary
Table S1. All mice were maintained on the C57BL/
6JRccHsd background. Animals were group-housed in
standard conditions of maintenance52. Food and water
were provided ad libitum. The mice were terminally
anesthetized with tribromoethanol (Avertin, Sigma-
Aldrich, St. Louis, MO) followed by decapitation without
transcardial perfusion. For each set of mice, cerebral
cortex area was isolated, weighed and maintained on ice
until isolation of mitochondrial fractions. Fresh-frozen
heart and cerebral cortex samples were also collected to
assess Respiratory Chain (RC) complex enzyme assays.
All experiments were approved by the national Animal
Experiment Board of Finland and followed the
animal protection guidelines of the Council of the
European Union.
Generation of CLN5 KO cell lines using CRISPR/Cas9 system
The CLN5 CRISPR single guide RNA (sgRNA)
sequence CATGCGCCGGAACCTGCGCT was designed
in order to efficiently target the CLN5 gene with a mini-
mal risk of off-target53, and the annealed guide oligodu-
plex was placed inside the pSpCas9(BB)-2A-Puro V2.0
plasmid (Addgene Plasmid #62988) backbone generating
the plasmid expression vectors used in this study. Con-
struct was then transformed into a competent E. coli
strain (One Shot Stbl3 Chemically Competent E. coli;
Invitrogen-ThermoFisher Scientific, Waltham, MA), and
the plasmid DNA was isolated (QIAprep® spin miniprep
Kit; Qiagen, Hilden, Germany) to check for the correct
insertion of CRISPR guide.
HEK 293T and SH-SY5Y cell lines were transfected by
Lipofectamine 3000 (Invitrogen-Thermo Fisher Scientific,
Waltham, MA) following the standard protocol, and the
transfection pool was puromycin selected (2 or 5 μg/mL
for HEK 293T and SH-SY5Y, respectively) prior to clone
isolation by “limiting-dilution technique”.
Clones grown under regular conditions (growing-time
≅ 3 weeks) were screened by Western blotting (WB)
analysis, and clones lacking CLN5-immunoreactivity were
evaluated by standard sequencing methods. Tracking of
Indels by Decomposition (TIDE) web tool (https://tide-
calculator.nki.nl), was used to accurately characterize and
quantify the induced genome editing events54. Two HEK
293T and one SH-SY5Y CLN5 stable KO clones (editing
efficiency > 80%) were selected for downstream analyses
(Supplementary Fig. S1a, b).
Oxygen consumption rate measurements
Oxygen consumption rate (OCR) was measured in KO
cell models and CLN5 cultured fibroblasts (together with
their respective controls), using an XFe24 Extracellular
Flux Analyzer (Seahorse Bioscience, Agilent, Santa Clara,
CA). Cells were plated in XF 24-well cell culture micro-
plates at a density of 6E+ 04 cells/well and 5E+ 04 cells/
well for cell lines and primary fibroblasts, respectively.
Measurements of endogenous respiration were per-
formed with non-buffered DMEM medium supple-
mented with 1 mM pyruvate, 2 mM glutamine and
10 mM glucose. After baseline measurements, OCR was
analyzed by the sequential injection of 1 mM of oligo-
mycin, 2 mM of carbonyl-cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) and 0.5 mM of rotenone plus
antimycin A (all chemical were from Sigma Aldrich, St.
Louis, MO). Data were expressed as pmol of O2/min
normalized post-assay by the fluorescence CyQUANT
Cell Proliferation Assays (Invitrogen™, Carlsbad, CA), as
reported elsewhere55.
Determination of reactive oxygen species
For the evaluation of intracellular reactive oxygen spe-
cies (ROS) production, a cellular ROS detection assay kit
(Abcam, Cambridge, UK) was used. Skin fibroblasts were
labeled with the oxidative stress marker 2′,7′-dichloro-
dihydrofluorescein diacetate (H2DCFDA), 25 μM for
45min at 37 °C and then cultured for an additional hour
in the presence/absence of 150 µM tert-butyl hydrogen
peroxide (TBHP), a ROS-mimic compound. Cells were
then analyzed on a SpectraMax® ID3 plate reader
(Molecular Devices, San Jose, CA) at a wavelengths Ex/
Em: 485/535 nm, and the difference in ROS levels
between treated and untreated condition were expressed
as relative fluorescent units (RFU) after background
subtraction. For each well DCF signal was normalized to
Hoechst 33342 intensity.
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Respiratory chain enzyme analysis in mouse tissues
The enzymatic activities of RC complexes were assayed
spectrophotometrically in fresh-frozen hearts and cere-
bral cortex from symptomatic mice comparing with age
matched wild-type littermates. Samples were homo-
genized in sucrose homogenization buffer (250 mM
sucrose, 20 mM Tris-HCl, 40 mM KCl, 2 mM EGTA, pH
7,4), and protein concentration was determined by BCA
assay method. RC kinetic assays were performed at 30 °C
using a Beckman Coulter DU760 (Beckman Coulter,
Pasadena, CA) spectrophotometer following standard
methods already reported56. Briefly, complex I (NADH:
ubiquinone reductase) activity was measured by the
rotenone sensitive oxidation of NADH at 340 nm, while
complex II (succinate dehydrogenase) activity was mea-
sured by the malonate sensitive reduction of succinate at
600 nm. Complex I/III (NADH:cytochrome c reductase)
activity was measured by NADH dependent of cyto-
chrome c at 550 nm, followed by complex II/III (succi-
nate:cytochrome c reductase) activity measured by
succinate dependent reduction of cytochrome c at
550 nm. Complex IV (cytochrome c oxidase activity) was
assessed by the oxidation of reduced cytochrome c at
550 nm. The enzymatic specific activities for each mito-
chondrial enzyme were calculated as nmol/min/mg of
protein and expressed as ratios in relation to the activity
of citrate synthase (CS), a mitochondrial matrix enzyme,
and determined by the formation of 5-thio-2-nitrobenzoic
acid at 412 nm.
Evaluation of mitochondrial membrane potential (ΔΨm)
Neuroblastoma cell lines were plated at 5E+ 04 cells/
well density in 96 well plates with normal growth med-
ium. Following 24 h of growth, the mitochondrial mem-
brane potential was measured using the fluorescent dye
tetramethylrhodamine methyl ester (TMRM, Invitrogen™,
Carlsbad, CA). The dye was loaded into cells in 100 nM in
bicarbonate and phenol red-free Hank’s balanced salt
solution (HBSS) supplemented with 10mM HEPES
(Sigma-Aldrich), 2 µM cyclosporine-H (CsH), pH 7.4 and
placed at 37 °C for 5 min. Fluorescence was measured on a
SpectraMax® ID3 plate reader (Molecular Devices, San
Jose, CA) (544/590 nm Ex/Em, bottom reading). Assay
was performed in parallel as described above with addi-
tion of 20 μM FCCP, which collapses the mitochondrial
membrane potential. All data were expressed as the total
TMRM relative fluorescence units (RFU) minus the FCCP
treated TMRM fluorescence and normalized to the
number of cells using 4′,6-diamidino-2-phenylindole
(DAPI) staining (358/461 nm Ex/Em, bottom reading).
Kinetic evaluation of ΔΨm was performed by live imaging
as previously reported57. Briefly, neuroblastoma cell lines
were seeded at 60% confluence on 35-mm glass bottom
dishes (WillCo Wells B.V., Amsterdam, The Netherlands)
and grown for two days in DMEM. Cells were incubated
in bicarbonate and phenol red-free HBSS, supplemented
with 10mM HEPES (Sigma-Aldrich) and 1.6 µM CsH and
loaded with 20 nM TMRM for 30min at 37 ˚C. Cellular
fluorescence images were acquired every minute using a
Nikon Ti2-E inverted microscope equipped with a DS-
Qi2Mc camera and collected with a Nikon ×60 Plan
Apocr λ (NA= 1.40) oil immersion objective, using a
TRITC filter set. After 5 min of baseline, oligomycin
(2.5 µM final concentration) was added to the media
recording sequential digital images for 15min. At the end
of each experiment, mitochondria were fully depolarized
by the addition of 4 µM FCCP. Clusters of mitochondria
(15–30 on average) were identified as regions of interest
(ROIs), and fields without cells were used as a back-
ground. In all sequential digital images and for each ROI,
the changes in fluorescence intensity were measured
using Image J software (https://imagej.nih.gov/ij/)58.
Fluorescence values were expressed as a percentage of
baseline (T0, 100%), and reported as average of ROIs ± SD
for each time point.
Proteome analyses
Cellular fractionation method for mitochondria
Isolation of mitochondrial fractions from HEK 293T cell
lysates and mice cerebral cortex was performed using
Qproteome Mitochondria Isolation Kit (Qiagen, Hilden,
Germany) according to manufacturer instructions. A
pellet from about 1E+ 07 HEK 293T cells (harvested
without trypsin) or 40mg of fresh cerebral cortex
homogenized tissue were processed to obtain high-purity
mitochondrial preparations. Solubilization of organelle
fractions was carried out in a lysis buffer containing 7M
urea, 2M thiourea, 4% CHAPS and protease inhibitors.
The protein concentration was determined using a col-
orimetric assay based on the Bradford method (Bio-Rad
Laboratories, Inc., Hercules, CA).
Sample preparation, proteolytic digestion and DIA-HDMSE
Ten µg of total protein from mitochondrial fraction
obtained from either HEK 293T cell lysate or mice cere-
bral cortex were digested using a modified FASP protocol
as described17. Three-hundred nanograms of digested
proteins (three technical replicates per sample) were used
for DIA (Data Independent Acquisition) HDMSE (High
Definition Mass Spectrometry) analysis. The parameters
of DIA-HDMSE runs were described previously58,59.
Database searches were carried out against human
(release 2017_48461 entries) or Mus musculus (release
2017_16869 entries) UniProtKB–Swiss-Prot, reviewed,
database with ion accounting algorithm and using the
following parameters: peptide and fragment tolerance:
automatic, maximum protein mass: 500 kDa, minimum
fragment ions matches per protein 7, fragment ions
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matches per peptide 3, peptide matches per protein 1,
primary digest reagent: trypsin, missed cleavages allowed:
2, fixed modification: carbamidomethylation C, variable
modifications: NQ deamidation, oxidation of methionine
(M) and false discovery rate (FDR) below 4%. Protein
quantitation was performed entirely on non-conflicting
protein identifications, using precursor ion intensity data
and standardized expression profiles. The proteomics data
were submitted to MassIVE (accession number
MSV000084880; https://doi.org/10.25345/C5PQ4G) and
ProteomeXchange (PXD017356).
Development of a scoring system for mitochondrial proteins
Additional filters were applied to final data set in order
to increase the stringency of accepted protein leads.
Protein identifiers (IDs) obtained in HDMSE analysis from
mitochondrial fractions were selected generating a rank-
ing for final score of mitochondrial confidence using
MitoMiner 4.0 v2018 JUN (http://mitominer.mrc-mbu.
cam.ac.uk), based on individual scores from various
mitochondrial and functional annotation databases, and
following a modified scheme from Laakkonen et al.59.
Criteria employed in the scoring system for mitochondrial
confidence are reported in Supplementary Table S3.
Identifiers with a total score of 6–8 were selected as
mitochondrial proteins of High Confidence (Mito HC
dataset) whereas IDs with a score 3 and 5, were selected as
hits with Medium Confidence (Mito MC dataset). IDs
with a score below 3 were discarded from the data set.
The number of unique peptides used for label-free
quantitation ≥2 further filtered all data sets; and fold
change (FC) from averaged, normalized protein intensities
≥1.3, for dataset from mice tissue and ≥1.5 for HEK 293T
cell line, in either direction of up- or down-regulation and
p ≤ 0.05 by ANOVA for all comparisons.
Immunofluorescence staining
The cells adherent on sterile glass coverslips, previously
treated with Poly-D-Lysine (Sigma-Aldrich) were fixed in
cold methanol for 20min and permeabilized with 0.1%
Triton X-100 in PBS1X for 15min. Coverslips were washed
in PBS and incubated in a blocking solution (FBS 20% in
PBS) for 1 h at room temperature. Overnight incubation at
4 °C was performed with the following primary antibodies:
mouse monoclonal anti-Porin (MitoScience; dilution 1:500),
mouse monoclonal anti-p62 (BD Transduction Laborator-
iesTM; dilution 1:200), rabbit polyclonal anti-TOMM20
(Santa Cruz Biotechnology Inc.; dilution 1:100), mouse
monoclonal anti-Human LAMP1 (BD PharmingenTM;
dilution 1:1000) and rabbit polyclonal anti-LC3B (Sigma-
Aldrich; dilution 1:1000). As secondary antibodies, goat anti-
mouse or anti-rabbit antibodies conjugated with AlexaFluor
488 or AlexaFluor 555 dye (Cell Signaling Technology Inc;
dilution 1:1000) were used for 1 h at room temperature in a
humid chamber. Nuclei were stained with the fluorescent
dye 4,6-diamidino- 2-phenylindole-dihydrochloride (5 µg/ml
DAPI, Sigma-Aldrich). Stained cells were mounted for
microscopy. Images were acquired using a Nikon Ti2-E
inverted microscope equipped with a DS-Qi2Mc camera
and collected with a Nikon ×60 Plan Apocr λ (NA= 1.40)
oil immersion objective, using a FITC, TRITC and DAPI
filter sets. Mitochondrial staining with MitoTracker Red
(Invitrogen-ThermoFisher Scientific), was performed using a
working concentration of 200 nM in regular medium for
30min. Following the incubation period, the cells were
washed twice in PBS prior to live imaging.
Western blotting
For Western blotting, samples were homogenized in
RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, 6 mM
EDTA, 1% NP-40, 0.1% SDS, 0.5% deoxycholic acid, pH
8.0) containing inhibitors of proteases (Roche Diagnostics
GmbH, Mannheim, Germany) and centrifuged for 10 min
at 14000×g at 4 °C. In all, 15–50 μg of protein lysates,
determined by BCA assay (Invitrogen-ThermoFisher
Scientific) was denatured and separated by electrophoresis
using 8–16% Tris-Glycine Mini Gels (Invitrogen-Ther-
moFisher Scientific) and then electro-blotted onto PVDF
membranes (Bio-Rad Laboratories Inc., Hercules, CA).
Membranes were blocked with TBS/0.1%-Tween20
(TTBS) containing 5% non-fat dry milk before overnight
incubation with the specified antibodies. Peroxidase-
conjugated anti-mouse and anti-rabbit secondary anti-
bodies (Jackson ImmunoResearch, Laboratories Inc.) were
added for 1 h at room temperature in the same buffer as
used for the primary antibodies (2.5% non-fat dry milk in
TTBS). Reactive bands were detected using Clarity
MaxTM Western ECL Substrate (Bio-Rad Laboratories
Inc.), according to the manufacturer’s instructions. Den-
sitometry of Western blot bands was performed with the
ImageJ software58. Primary antibodies used for Western
blotting analysis were as follows: rabbit monoclonal anti-
CLN5 [EPR12197(B)] (Abcam #ab170899; dilution
1:1000), mouse monoclonal anti-P62 (BD biosciences
#610832; dilution 1:1000), rabbit monoclonal anti-LC3B
(Sigma-Aldrich #L7543; dilution 1:1000), rabbit poly-
clonal anti-ACO2 (Bethyl laboratories #A305–302A-M;
dilution 1:1000), rabbit polyclonal anti- ATP5L (Bethyl
laboratories #A305–486A-M; dilution 1:500), mouse
monoclonal anti-FUNDC (Santa Cruz Biotechnology #sc-
517152; dilution 1:500). Immunodetection with mouse
monoclonal anti-GAPDH antibody [6C5] (Abcam #
ab8245; dilution 1:8000) served as a loading control to
normalize the bands intensity.
Statistical analyses
Data presentation and statistical analyses were per-
formed using Prism 8 (GraphPad Software, San Diego
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CA). For functional studies and Western blot analysis,
data were presented, stating n as a mean ± standard
deviation (SD) from at least three independent experi-
ments. Statistical analyses utilized Student t test with
significance set at P < 0.05 (*), P < 0.01 (**), and P < 0.001
(***). For proteome analysis, six different mitochondrial
fractions from two distinct CLN5 KO genotypes were
compared with three mitochondrial samples obtained
from a Ctrl cell line. Each biological replicate was ana-
lyzed in technical triplicates. To compare the controls and
KO lines, we utilized the between-subject design scheme
of the Progenesis QITM software (Nonlinear Dynamics,
Durham, NC). The ANOVA calculation applied by this
scheme assumes that the conditions are independent and
used a statistical test which presumes that means of the
conditions are equal and the variance similar between the
groups. P values ≤ 0.05 by ANOVA were considered as
significant.
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